Mr. John Hennessy:

Yes, I would hope so. The purpose of our meeting with the company is to establish what its intentions are towards that group of patients. As I mentioned, there is a pretty well established protocol for the management of patients at the end of clinical trials and access programmes and we will be calling on that company to adhere to those protocols.